FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2195280390> ?p ?o ?g. }

• W2195280390 endingPage "1554" @default.
• W2195280390 startingPage "1550" @default.
• W2195280390 abstract "Previous studies have determined the short-term toxicity profile, laboratory changes, and clinical efficacy associated with hydroxyurea (HU) therapy in adults with sickle cell anemia. The safety and efficacy of this agent in pediatric patients with sickle cell anemia has not been determined. Children with sickle cell anemia, age 5 to 15 years, were eligible for this multicenter Phase I/II trial. HU was started at 15 mg/kg/d and escalated to 30 mg/kg/d unless the patient experienced laboratory toxicity. Patients were monitored by 2-week visits to assess compliance, toxicity, clinical adverse events, growth parameters, and laboratory efficacy associated with HU treatment. Eighty-four children were enrolled between December 1994 and March 1996. Sixty-eight children reached maximum tolerated dose (MTD) and 52 were treated at MTD for 1 year. Significant hematologic changes included increases in hemoglobin concentration, mean corpuscular volume, mean corpuscular hemoglobin, and fetal hemoglobin parameters, and decreases in white blood cell, neutrophil, platelet, and reticulocyte counts. Laboratory toxicities typically were mild, transient, and were reversible upon temporary discontinuation of HU. No life-threatening clinical adverse events occurred and no child experienced growth failure. This Phase I/II trial shows that HU therapy is safe for children with sickle cell anemia when treatment was directed by a pediatric hematologist. HU in children induces similar laboratory changes as in adults. Phase III trials to determine if HU can prevent chronic organ damage in children with sickle cell anemia are warranted." @default.
• W2195280390 created "2016-06-24" @default.
• W2195280390 creator A5004752879 @default.
• W2195280390 creator A5019213429 @default.
• W2195280390 creator A5024752787 @default.
• W2195280390 creator A5026343920 @default.
• W2195280390 creator A5040752648 @default.
• W2195280390 creator A5056946591 @default.
• W2195280390 creator A5060034574 @default.
• W2195280390 creator A5068017197 @default.
• W2195280390 creator A5068998171 @default.
• W2195280390 creator A5074300453 @default.
• W2195280390 creator A5087371438 @default.
• W2195280390 date "1999-09-01" @default.
• W2195280390 modified "2023-10-03" @default.
• W2195280390 title "Safety of Hydroxyurea in Children With Sickle Cell Anemia: Results of the HUG-KIDS Study, a Phase I/II Trial" @default.
• W2195280390 cites W1488638920 @default.
• W2195280390 cites W1719867626 @default.
• W2195280390 cites W1964620166 @default.
• W2195280390 cites W2019018139 @default.
• W2195280390 cites W2066875500 @default.
• W2195280390 cites W2068138954 @default.
• W2195280390 cites W2117054170 @default.
• W2195280390 cites W2153336025 @default.
• W2195280390 cites W2313541759 @default.
• W2195280390 cites W2464605913 @default.
• W2195280390 cites W4860913 @default.
• W2195280390 doi "https://doi.org/10.1182/blood.v94.5.1550" @default.
• W2195280390 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10477679" @default.
• W2195280390 hasPublicationYear "1999" @default.
• W2195280390 type Work @default.
• W2195280390 sameAs 2195280390 @default.
• W2195280390 citedByCount "143" @default.
• W2195280390 countsByYear W21952803902012 @default.
• W2195280390 countsByYear W21952803902013 @default.
• W2195280390 countsByYear W21952803902014 @default.
• W2195280390 countsByYear W21952803902015 @default.
• W2195280390 countsByYear W21952803902016 @default.
• W2195280390 countsByYear W21952803902017 @default.
• W2195280390 countsByYear W21952803902018 @default.
• W2195280390 countsByYear W21952803902019 @default.
• W2195280390 countsByYear W21952803902020 @default.
• W2195280390 countsByYear W21952803902021 @default.
• W2195280390 countsByYear W21952803902022 @default.
• W2195280390 countsByYear W21952803902023 @default.
• W2195280390 crossrefType "journal-article" @default.
• W2195280390 hasAuthorship W2195280390A5004752879 @default.
• W2195280390 hasAuthorship W2195280390A5019213429 @default.
• W2195280390 hasAuthorship W2195280390A5024752787 @default.
• W2195280390 hasAuthorship W2195280390A5026343920 @default.
• W2195280390 hasAuthorship W2195280390A5040752648 @default.
• W2195280390 hasAuthorship W2195280390A5056946591 @default.
• W2195280390 hasAuthorship W2195280390A5060034574 @default.
• W2195280390 hasAuthorship W2195280390A5068017197 @default.
• W2195280390 hasAuthorship W2195280390A5068998171 @default.
• W2195280390 hasAuthorship W2195280390A5074300453 @default.
• W2195280390 hasAuthorship W2195280390A5087371438 @default.
• W2195280390 hasConcept C126322002 @default.
• W2195280390 hasConcept C172680121 @default.
• W2195280390 hasConcept C187212893 @default.
• W2195280390 hasConcept C197934379 @default.
• W2195280390 hasConcept C2776317666 @default.
• W2195280390 hasConcept C2778248108 @default.
• W2195280390 hasConcept C2778620579 @default.
• W2195280390 hasConcept C2778715236 @default.
• W2195280390 hasConcept C2778917026 @default.
• W2195280390 hasConcept C2779134260 @default.
• W2195280390 hasConcept C2779234561 @default.
• W2195280390 hasConcept C2780554921 @default.
• W2195280390 hasConcept C2781058662 @default.
• W2195280390 hasConcept C29730261 @default.
• W2195280390 hasConcept C535046627 @default.
• W2195280390 hasConcept C54355233 @default.
• W2195280390 hasConcept C71924100 @default.
• W2195280390 hasConcept C86803240 @default.
• W2195280390 hasConcept C90924648 @default.
• W2195280390 hasConceptScore W2195280390C126322002 @default.
• W2195280390 hasConceptScore W2195280390C172680121 @default.
• W2195280390 hasConceptScore W2195280390C187212893 @default.
• W2195280390 hasConceptScore W2195280390C197934379 @default.
• W2195280390 hasConceptScore W2195280390C2776317666 @default.
• W2195280390 hasConceptScore W2195280390C2778248108 @default.
• W2195280390 hasConceptScore W2195280390C2778620579 @default.
• W2195280390 hasConceptScore W2195280390C2778715236 @default.
• W2195280390 hasConceptScore W2195280390C2778917026 @default.
• W2195280390 hasConceptScore W2195280390C2779134260 @default.
• W2195280390 hasConceptScore W2195280390C2779234561 @default.
• W2195280390 hasConceptScore W2195280390C2780554921 @default.
• W2195280390 hasConceptScore W2195280390C2781058662 @default.
• W2195280390 hasConceptScore W2195280390C29730261 @default.
• W2195280390 hasConceptScore W2195280390C535046627 @default.
• W2195280390 hasConceptScore W2195280390C54355233 @default.
• W2195280390 hasConceptScore W2195280390C71924100 @default.
• W2195280390 hasConceptScore W2195280390C86803240 @default.
• W2195280390 hasConceptScore W2195280390C90924648 @default.
• W2195280390 hasIssue "5" @default.
• W2195280390 hasLocation W21952803901 @default.
• W2195280390 hasOpenAccess W2195280390 @default.

• next